Hepatitis C in Developing Countries: Current and Future Challenges explores the current state of HCV in several countries, including Africa, Asia and South America. It maintains a dedicated focus on the epidemiology, clinical patterns, virologic diversity, coinfections, natural history and progression, complications, and response to standard of care (SOC) pegylated interferon and ribavirin therapy of HCV with recommendations specific to middle and low income countries. Readers will find detailed information on the burden of HCV infection from a global health and economic perspective, along with data from multicenter trials on DAAs that have enrolled patients infected with HCV non-genotype 1.
1. Global Burden of Hepatitis C Section 1.1 The Public Health and Health Care Burden of Hepatitis C Infection Section 1.2 The Economic Burden of Hepatitis C Infection Section 1.3 The Social Burden of Hepatitis C Infection 2. The Epidemic of Hepatitis C in Developing Countries Section 2.1 HCV Statistics in Developing Countries Section 2.2 The Growing Challenge of Hepatitis C in Developing Countries Subsection 2.2.a Epidemiology of Hepatitis C in Developing Countries Subsection 2.2.b Modes of Transmission of Hepatitis C in Developing Countries Subsection 2.2 c Socio-political Aspects of Hepatitis C in Developing Countries Subsection 2.2.d. Hepatitis C Genotypes in Developing Countries Subsection 2.2 e. Clinical Patterns and Complications of Hepatitis C Infection in Developing Countries Subsection 2.2.e Access to Hepatitis C Treatment in Developing Countries Subsection 2.2.f. Impact of Coinfections on Hepatitis C in Developing Countries Section 2.3 Macro and Micro-economics of Hepatitis C in Developing Countries 3. The Magnitude of Hepatitis C Problem in Specific Regions Section 3.1 Hepatitis C in Egypt Section 3.2 Hepatitis C in Africa Section 3.3 Hepatitis C in the Middle East Section 3.1 Hepatitis C in Indian Subcontinent Section 3.2 Hepatitis C in Latin America Section 3.3 Hepatitis C in Southeast Asia 4. Challenges of Hepatitis C in Developing Countries Section 4.1 Direct Acting Antiviral Agents in Developing Countries Section 4.2 Challenges of Producing Drugs and Potential Vaccines for Hepatitis C Specifically for Developing Countries Section 4.3 Ethics of Hepatitis C Clinical Trials and Research in Developing Countries Section 4.4 Applications of Genetics in Developing Countries Section 4.5 Hepatitis C Surveillance and Prevention in Developing Countries
Professor Sanaa Kamal works at the Department of Gastroenterology and Hepatology within in the Ain Shams Faculuty of Medicine. She is a leading authority on the treatment and stidy of hepatitis C.